Authors

    Language

    English

    Publication Date

    3-1-2022

    Journal

    Gut

    DOI

    10.1136/gutjnl-2021-326170

    PMID

    34750206

    PMCID

    PMC8828664

    PubMedCentral® Posted Date

    3-1-2022

    PubMedCentral® Full Text Version

    Author MSS

    Abstract

    Helicobacter pylori infections are responsible for tremendous morbidity and mortality worldwide, leading to efforts to eradicate the organism. However, the effectiveness of antimicrobial therapy has been undermined by the progressive development of antimicrobial resistance. Treatments and treatment guidelines have been based on traditional pairwise meta-analyses of randomized controlled trials. More recently, network meta-analyses have also been utilized in an attempt to provide useful information to the clinician regarding which therapies appear best and which to avoid as the least efficacious. However, both forms of meta-analysis have been undermined by the same problems including the poor quality of the clinical trials using unoptimized regimens and incomparable comparisons related to marked geographic and ethnic genotypic and phenotypic heterogeneity. In addition, the comparator regimens often consist of invalid strawman comparisons. New approaches concerning H. pylori treatment and analysis of therapies are needed. H. pylori therapies should be based on antimicrobial stewardship, as in other infectious diseases. This approach requires the use of only optimized therapies proven to be reliably highly effective in the local population (e.g., a cure rate of ≥90%) for both the study and the comparator regimens. Meta-analyses should be restricted to regimens that meet these criteria and must take into account the presence of marked geographic and host genetic and phenotypic heterogeneity. In addition, to provide clinically relevant results, treatment outcomes should focus on, and present, actual cure rates in addition to odd ratios.

    Keywords

    Anti-Bacterial Agents, Helicobacter Infections, Helicobacter pylori, Humans, Network Meta-Analysis, Helicobacter pylori; treatment; antimicrobial therapy, cure rates; randomized control trial; meta-analysis; network meta-analysis; heterogeneity; strawman comparisons

    Published Open-Access

    yes

    Share

    COinS
     
     

    To view the content in your browser, please download Adobe Reader or, alternately,
    you may Download the file to your hard drive.

    NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.